PHARMACYTE BIOTECH, INC. Preferred Stock, Accretion of Redemption Discount
PHARMACYTE BIOTECH, INC. (PMCB) reported Preferred Stock, Accretion of Redemption Discount of $621.22 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.
Financial Statements › Shareholders' Equity
us-gaap:PreferredStockAccretionOfRedemptionDiscount · last filed 2026-09-14
- PHARMACYTE BIOTECH, INC. preferred stock, accretion of redemption discount for the quarter ending 2026-07-31 was $621.22K.
- PHARMACYTE BIOTECH, INC. preferred stock, accretion of redemption discount for the quarter ending 2026-04-30 was $396.57K.
- PHARMACYTE BIOTECH, INC. preferred stock, accretion of redemption discount for the quarter ending 2026-01-31 was $2.20M.
- PHARMACYTE BIOTECH, INC. preferred stock, accretion of redemption discount for the quarter ending 2025-10-31 was $902.00K, a 13.71% decline year-over-year.
- PHARMACYTE BIOTECH, INC. preferred stock, accretion of redemption discount for fiscal 2026 was $3.50M, a 9.70% increase from fiscal 2025.
- PHARMACYTE BIOTECH, INC. preferred stock, accretion of redemption discount for fiscal 2025 was $3.19M, a 78.79% decline from fiscal 2024.
- PHARMACYTE BIOTECH, INC. preferred stock, accretion of redemption discount for fiscal 2024 was $15.05M.
- PHARMACYTE BIOTECH, INC. preferred stock, accretion of redemption discount for fiscal 2023 was $0.00.
| Period end | Preferred Stock, Accretion of Redemption Discount 3 month | Preferred Stock, Accretion of Redemption Discount 6 month | Preferred Stock, Accretion of Redemption Discount 9 month | Preferred Stock, Accretion of Redemption Discount 12 month |
|---|---|---|---|---|
| 2026-07-31 | $621.22K 10-Q · filed 2026-09-14 | $1.02M derived: sum of 2 quarters · filed 2026-09-14 | $3.22M derived: sum of 3 quarters · filed 2026-09-14 | $4.12M derived: sum of 4 quarters · filed 2026-09-14 |
| 2026-04-30 | $396.57K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | $2.60M derived: sum of 2 quarters · filed 2026-07-29 | $3.50M derived: sum of 3 quarters · filed 2026-07-29 | $3.50M 10-K · filed 2026-07-29 |
| 2026-01-31 | $2.20M 10-Q · filed 2026-03-17 | $3.11M derived: sum of 2 quarters · filed 2026-03-17 | $3.11M 10-Q · filed 2026-03-17 | $3.11M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-10-31 | $902.00K 10-Q · filed 2025-12-18 | $902.00K 10-Q · filed 2025-12-18 | $902.00K derived: sum of 3 quarters · filed 2026-09-14 | $902.00K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-07-31 | $0.00 10-Q · filed 2026-09-14 | $0.00 derived: sum of 2 quarters · filed 2026-09-14 | $0.00 derived: sum of 3 quarters · filed 2026-09-14 | $1.05M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | $0.00 derived: sum of 2 quarters · filed 2026-07-29 | $1.05M derived: sum of 3 quarters · filed 2026-07-29 | $3.19M 10-K · filed 2026-07-29 |
| 2025-01-31 | $0.00 10-Q · filed 2026-03-17 | $1.05M derived: sum of 2 quarters · filed 2026-03-17 | $3.19M 10-Q · filed 2026-03-17 | $6.25M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-10-31 | $1.05M 10-Q · filed 2025-12-18 | $3.19M 10-Q · filed 2025-12-18 | $6.25M derived: sum of 3 quarters · filed 2025-12-18 | $10.47M derived: sum of 4 quarters · filed 2025-12-18 |
| 2024-07-31 | $2.15M 10-Q · filed 2025-09-15 | $5.21M derived: sum of 2 quarters · filed 2025-09-15 | $9.42M derived: sum of 3 quarters · filed 2025-09-15 | $13.89M derived: sum of 4 quarters · filed 2025-09-15 |
| 2024-04-30 | $3.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-11 | $7.28M derived: sum of 2 quarters · filed 2025-08-11 | $11.74M derived: sum of 3 quarters · filed 2025-08-11 | $15.05M 10-K · filed 2025-08-11 |
| 2024-01-31 | $4.22M 10-Q · filed 2025-03-17 | $8.68M derived: sum of 2 quarters · filed 2025-03-17 | $12.00M 10-Q · filed 2025-03-17 | $11.95M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-10-31 | $4.46M 10-Q · filed 2024-12-13 | $7.73M 10-Q · filed 2024-12-13 | $7.73M derived: sum of 3 quarters · filed 2024-12-13 | $7.73M derived: sum of 4 quarters · filed 2024-12-13 |
| 2023-07-31 | $3.27M 10-Q · filed 2024-09-17 | $3.27M derived: sum of 2 quarters · filed 2024-09-17 | $3.27M derived: sum of 3 quarters · filed 2024-09-17 | |
| 2023-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-13 | $0.00 derived: sum of 2 quarters · filed 2024-08-13 | $0.00 10-K · filed 2024-08-13 | |
| 2023-01-31 | $0.00 10-Q · filed 2024-03-18 | $0.00 10-Q · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |